By Karen Roman
Sequana Medical NV (BRU: SEQUA.BR) said it successfully implanted the alfapump device for treatment of recurrent or refractory ascites due to liver cirrhosis in two patients at the University of Pennsylvania.
The alfapump is the first FDA-approved active implantable medical device to automatically remove ascitic fluid from the abdomen, freeing patients of repeated and invasive drainage procedures, the company stated.
This is the second U.S. medical site where the alfapump has been successfully implanted, following the first at Mount Sinai Hospital in New York in November 2025, it said.
“Here is another top-tier US hospital with a strong reputation in hepatology and interventional radiology starting to implant the alfapump in a commercial setting, and we are proud to work alongside them to deliver this breakthrough device to patients that currently undergo repeated needle puncture paracentesis,” said Martijn Blom, Sequana Medical’s Chief Commercial Officer.
READ MORE
5th Palm Beach CorpGov Forum Highlights & Look Ahead
Never Miss our Weekly Highlights HERE
